New York - Two of four Ebola treatment drugs have been determined "more effective" than the others and will be the only ones used on patients going forward, the World Health Organisation announced on Monday.
In a multi-drug randomised trial that began as a part of the emergency response in the Democratic Republic of Congo on November 20, 2018, two of the four Ebola treatment drugs were determined more effective in treating patients than others, the WHO said. The trial was called the Pamoja Tulinde Maisha study.
ZMapp, remdesivir, mAb114 and REGN-EB3 were the four drugs used in the trials. During trials, REGN-EB3 and mAb114 were determined to be more effective in treating Ebola than the other two, and will be the only two used going forward, the National Institute of Allergy and Infectious Diseases announced.
As part of an emergency response team in the Congo, the "Together Save Lives" trial was done with a collaboration of organisations, including the Congo's National Institute for Biomedical Research, the Ministry of Health, the NIH's National Institute of Allergy and Infectious Diseases, the Alliance for International Medical Action and other organisations.
Although the final analysis of data will be completed in late September or early October of this year, the NIAID said the effectiveness of REGN-EB3 and mAb114 was "compelling enough to recommend and implement" the changes immediately. The other two treatments, ZMapp and remdesivir, will no longer be used.